ADOCIA Announces the Live Broadcast of its Annual General Meeting on May 20th, 2021
May 11 2021 - 12:00PM
Business Wire
Regulatory News:
ADOCIA (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC – the
company) a clinical stage biopharmaceutical company focused on
diabetes treatment with innovative formulations of approved
proteins, confirms that it will hold its Annual General Meeting
("AGM") on May 20, 2021 at 10:00 a.m., at Adocia's offices, 115
avenue Lacassagne, 69003, Lyon, France.
The Shareholders' Meeting will also be broadcast live on the
Company's website (www.adocia.com under "Investors - Shareholder
Meeting") by audio webcast via conference call without possibility
to interact.
The video will be available on a deferred basis within the
timeframe provided for by the regulations.
All documentation concerning the Meeting is available to
shareholders in accordance with the conditions set out in the
regulations in force, and is available on the Company's website:
https://www.adocia.com/investors-welcome/shareholders-meeting/
Precisions regarding the
AGM:
Only shareholders having registered their shares at least two
business days prior to the date of the AGM, by midnight Paris time,
will be able to participate physically in the AGM. Shareholders
holding bearer shares (“actions au porteur”) will need to obtain a
certificate of shareholding (“attestation de participation”) from
their brokers. This certificate must be attached to the proxy form
or to the appropriate voting form if shareholders wish to designate
a proxy or vote by post. The “attestation de participation” may
replace the admission card for shareholders wishing to attend the
AGM in person.
Each shareholder may submit a question in writing to the Board
of Directors, this question being treated during the shareholders
meeting. Questions should be sent by registered mail with return
receipt to the following address: ADOCIA, 115 avenue Lacassagne -
69003 Lyon or electronic communication to the following address:
ag2021@adocia.com.The written question must imperatively be
accompanied by a certificate of attendance in order to be treated
and must be sent no later than the fourth business day preceding
the date of the general meeting.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring four clinical-stage products. The
proprietary BioChaperone® technological platform is designed to
enhance the effectiveness and/or safety of therapeutic proteins
while making them easier for patients to use. Adocia customizes
BioChaperone to each protein for a given application.
Adocia’s clinical pipeline includes four novel insulin
formulations for prandial treatment of diabetes: two ultra-rapid
formulations of insulin analog lispro (BioChaperone® Lispro U100
and U200), a combination of basal insulin glargine and rapid acting
insulin lispro (BioChaperone® Combo) and one combination of a
prandial insulin with amylin analog pramlintide M1Pram. The
clinical pipeline also includes an aqueous formulation of human
glucagon (BioChaperone® Glucagon) for the treatment of
hypoglycemia.
Adocia preclinical pipeline includes four products: combinations
of rapid human insulin analogues and Pramlintide (BioChaperone®
LisPram and BioChaperone® AsPram), a combination of insulin
glargine with GLP-1 receptor agonists (BioChaperone® Glargine
GLP-1) for the treatment of diabetes and a ready-to-use combination
of glucagon and a GLP-1 receptor agonist (BioChaperone® Glucagon
GLP-1) for the treatment of obesity.
Adocia recently added a fifth program, a preclinical stage cell
therapy initiative focused on development of a hydrogel scaffold
for use in people with type 1 diabetes. The first patent
application supporting this program has been filed.
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Universal Registration Document filed
with the French Autorité des marchés financiers on April 20, 2021
(a copy of which is available at www.adocia.com) and to the development of economic
conditions financial markets and the markets in which Adocia
operates. The forward-looking statements contained in this press
release are also subject to risks not yet known to Adocia or not
currently considered material by Adocia. The occurrence of all or
part of such risks could cause actual results, financial
conditions, performance, or achievements of Adocia to be materially
different from such forward-looking statements. This press release
and the information contained herein do not constitute an offer to
sell or the solicitation of an offer to buy Adocia shares in any
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210511005915/en/
Adocia Gérard Soula CEO contactinvestisseurs@adocia.com Ph: +33
4 72 610 610 www.adocia.com
MC Services AG Adocia Press Relations Europe Raimund Gabriel
Managing Partner adocia@mc-services.eu Ph: +49 89 210 228 0
The Ruth Group Adocia Investor Relations USA James Salierno
Vice-President jsalierno@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2023 to Apr 2024